BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Oct 17, 2019
Financial News

Innate gains dual listing, tops off fund-raise with private placement

With the $68.8 million raised through a NASDAQ listing and concurrent private placement, Innate plans to commercialize its sole approved cancer therapy and advance its clinical and preclinical pipeline. Innate Pharma S.A. (Euronext:IPH; NASDAQ:IPHA) gained...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
BioCentury | Dec 1, 2017
Clinical News

Innate sees no development path for lirilumab combo therapies

Innate Pharma S.A. (Euronext:IPH) said efficacy data from a Phase I/II trial of lirilumab (BMS-986015, IPH2102) in combination with Opdivo nivolumab to treat head and neck cancers "did not provide clear evidence of benefit to...
BioCentury | Nov 30, 2017
Clinical News

Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome who were killer cell immunoglobulin-like receptor...
BioCentury | Feb 10, 2017
Clinical News

Lirilumab: Ph II EffiKIR data

Top-line data from the double-blind, French Phase II EffiKIR trial in about 150 elderly AML patients in first complete remission showed that maintenance treatment with 0.1 mg/kg lirilumab every 3 months and 1 mg/kg lirilumab...
BioCentury | Feb 6, 2017
Clinical News

Innate's lirilumab fails Phase II AML trial

Innate Pharma S.A. (Euronext:IPH) lost EUR 2.05 (16%) to EUR 11.05 on Monday after it said lirilumab ( IPH2102 ) missed the primary endpoint in the Phase II EffiKIR trial to treat elderly patients with acute myelogenous...
BioCentury | Nov 11, 2016
Clinical News

Lirilumab: Ph I/II CA223-001 data

Data from a cohort of 29 evaluable patients with advanced platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) in the open-label, dose-escalation, international Phase I/II CA223-001 trial showed that IV lirilumab every 4...
BioCentury | Nov 4, 2016
Clinical News

IPH4102: Preliminary Ph I data

Preliminary data from 16 evaluable patients with KIR3dL2-positive, relapsed or refractory CTCL in the dose-escalation portion of the open-label, international Phase I IPH4102-101 trial showed that 0.0001-1.5 mg/kg doses of IV IPH4102 were well tolerated...
BioCentury | Oct 10, 2016
Clinical News

Lirilumab: Phase II ongoing

A DSMB recommended for the seventh time continuation of the double-blind, placebo-controlled, French Phase II EffiKIR trial evaluating 0.1 and 1 mg/kg lirilumab based on a safety analysis. The trial completed enrollment of about 150...
Items per page:
1 - 10 of 26